Track topics on Twitter Track topics that are important to you
Cancer Genetics has settled its failed merger deal with NovellusDx, paying $1.1 million in cash and $450,000 over nine months -More-
Note Payment Received from Interpace Diagnostics Group, Inc. Settlement Agreement with NovellusDx Restructured Note Agreement with Unsecured Lender M&A Advisory Agreement with H.C. ...
NovellusDx early detection test is a simple to perform blood test, which identifies the deregulated signaling pathways within the patient tumor based on protein secretion to the blood, th...
NovellusDx is developing a diagnostic platform for the early detection of cancer and a platform for personalized cancer therapy based on patient derived tumor tissue. The assay is able to ...
A precision oncology company that developed a novel live cell based assay to characterize the activity of unknown cancer mutations and test their response to targeted therapies. N...
We have published hundreds of NovellusDx news stories on BioPortfolio along with dozens of NovellusDx Clinical Trials and PubMed Articles about NovellusDx for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of NovellusDx Companies in our database. You can also find out about relevant NovellusDx Drugs and Medications on this site too.
Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...
An assay is an analytic procedure for qualitatively assessing or quantitatively measuring the presence or amount or the functional activity of a target entity. This can be a drug or biochemical substance or a cell in an organism or organic sample. ...